{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T01:40:28Z","timestamp":1729474828233,"version":"3.27.0"},"posted":{"date-parts":[[2024,6,18]]},"group-title":"In Review","reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,24]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Purpose. <\/bold>Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment in multiple myeloma (MM) but is associated with toxicities that impact quality of life (QoL). This study aimed (1) to describe the levels and evolution of QoL scores of newly diagnosed MM patients who received upfront tandem autologous + nonmyeloablative allogeneic HCT, and (2) to evaluate the impact of chronic graft-versus-host disease (cGVHD) on QoL. \n<bold>Methods. <\/bold>After induction and autologous HCT, patients were invited to participate in a prospective phase II study of tandem nonmyeloablative allogeneic HCT followed by bortezomib maintenance for one year. Participants completed questionnaires assessing QoL and cGVHD before allogeneic HCT (T1), then every three months during treatment (T2 to T6) and after treatment cessation (T7 to T10). \n<bold>Results. <\/bold>Thirty-three patients were included. Participants had high levels of QoL at all measurement times. Cognitive functioning and global health status decreased significantly during treatment (T1 vs. T2-T5), while fatigue symptoms were reported more frequently. After treatment cessation (T7-T10), only cognitive functioning remained significantly impacted. In contrast, participants reported a better emotional well-being after transplant (T1 vs. T2, T4-T10). Furthermore, as QoL scores were more frequently associated to lung, energy and psychological cGVHD domains. \n<bold>Conclusion. <\/bold>Our study demonstrates preservation of QoL during this upfront tandem treatment including autologous transplant followed by allogeneic HCT. Some identified domains impacting QoL may support therapeutic actions such as supportive care including psychological and neuropsychological interventions, as well as adapted physical activity in this population.\nThis trial was registered on 01\/12\/2014 to ClinicalTrial.gov: NCT02308280.<\/p>","DOI":"10.21203\/rs.3.rs-4470765\/v1","type":"posted-content","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:41:07Z","timestamp":1718988067000},"source":"Crossref","is-referenced-by-count":0,"title":["Quality of Life in High-Risk Myeloma Patients Treated with Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance"],"prefix":"10.21203","author":[{"given":"Valentyn","family":"Fournier","sequence":"first","affiliation":[{"name":"University of Lille"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ogez","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Leblanc","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristopher","family":"Lamore","sequence":"additional","affiliation":[{"name":"University of Lille"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Cancer Institute. Cancer Stat Facts: Myeloma. Surveillance, Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (accessed 22 Apr2024)."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","article-title":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction","volume":"137","author":"Fraz MA","year":"2019","unstructured":"Fraz MA, Warraich FH, Warraich SU, Tariq MJ, Warraich Z, Khan AY et al. Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Critical Reviews in Oncology\/Hematology 2019; 137: 18\u201326.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark C","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist U-H, Landgren O, Bj\u00f6rkholm M, Hultcrantz M et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100: 107\u2013113.","journal-title":"Haematologica"},{"year":"2016","author":"Ramsenthaler C","key":"ref4","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. 2016.https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-84991434402&doi=10.1111%2fejh.12790&partnerID=40&md5=a55cec20cce1a42c3152a085a586aaf7."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.6004\/jnccn.2009.0061","article-title":"NCCN clinical practice guidelines in oncology: multiple myeloma","volume":"7","author":"Anderson KC","year":"2009","unstructured":"Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 2009; 7: 908\u2013942.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar SV","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95: 548\u2013567.","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2015.319","article-title":"Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation","volume":"51","author":"Ahmad I","year":"2016","unstructured":"Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G et al. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant 2016; 51: 529\u2013535.","journal-title":"Bone Marrow Transplant"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40487-022-00195-3","article-title":"Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma","volume":"10","author":"Claveau J-S","year":"2022","unstructured":"Claveau J-S, Buadi FK, Kumar S. Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Oncol Ther 2022; 10: 105\u2013122.","journal-title":"Oncol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/07357909309024860","article-title":"Quality of Life in Cancer: Definition, Purpose, and Method of Measurement","volume":"11","author":"Cella DF","year":"1993","unstructured":"Cella DF, Tulsky DS. Quality of Life in Cancer: Definition, Purpose, and Method of Measurement. Cancer Investigation 1993; 11: 327\u2013336.","journal-title":"Cancer Investigation"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1007\/s00520-022-06943-5","article-title":"A cross-sectional observational study of health-related quality of life in adults with multiple myeloma","volume":"30","author":"LeBlanc MR","year":"2022","unstructured":"LeBlanc MR, Bryant AL, LeBlanc TW, Yang Q, Sellars E, Chase CC et al. A cross-sectional observational study of health-related quality of life in adults with multiple myeloma. Support Care Cancer 2022; 30: 5239\u20135248.","journal-title":"Support Care Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage","volume":"121","author":"Kent EE","year":"2015","unstructured":"Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer 2015; 121: 758\u2013765.","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/cncr.34134","article-title":"Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma","volume":"128","author":"O\u2019Donnell EK","year":"2022","unstructured":"O\u2019Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 2022; 128: 1996\u20132004.","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2013.228","article-title":"High prevalence of distress in patients after allogeneic hematopoietic SCT: Fear of progression is associated with a younger age","volume":"49","author":"Hefner J","year":"2014","unstructured":"Hefner J, Kapp M, Drebinger K, Dannenmann A, Einsele H, Grigoleit G-U et al. High prevalence of distress in patients after allogeneic hematopoietic SCT: Fear of progression is associated with a younger age. Bone Marrow Transplant 2014; 49: 581\u2013584.","journal-title":"Bone Marrow Transplant"},{"key":"ref14","first-page":"488","article-title":"Suicidal ideation in the clinical context of hematopoietic stem cell transplantation. A systematic review","volume":"22","author":"Hefner J","year":"2016","unstructured":"Hefner J, Mielke S, Csef H. Suicidal ideation in the clinical context of hematopoietic stem cell transplantation. A systematic review. ONKOLOGE 2016; 22: 488\u2013492.","journal-title":"ONKOLOGE"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/cncr.30546","article-title":"Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation","volume":"123","author":"El-Jawahri A","year":"2017","unstructured":"El-Jawahri A, Chen Y-B, Brazauskas R, He N, Lee SJ, Knight JM et al. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer 2017; 123: 1828\u20131838.","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease","volume":"23","author":"Kurosawa S","year":"2017","unstructured":"Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H et al. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 2017; 23: 1749\u20131758.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala J","year":"2011","unstructured":"Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011; 117: 4651\u20134657.","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1080\/10428194.2021.1953011","article-title":"Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting","volume":"62","author":"Asrar MM","year":"2021","unstructured":"Asrar MM, Lad DP, Bansal D, Prinja S, Khadwal A, Prakash G et al. Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. Leuk Lymphoma 2021; 62: 3271\u20133277.","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0269216319833588","article-title":"Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study","volume":"33","author":"Ramsenthaler C","year":"2019","unstructured":"Ramsenthaler C, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study. Palliat Med 2019; 33: 541\u2013551.","journal-title":"Palliat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond AS","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361\u2013370.","journal-title":"Acta Psychiatr Scand"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41409-021-01532-2","article-title":"Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous\/allogeneic transplant followed by bortezomib maintenance: a phase II study","volume":"57","author":"LeBlanc R","year":"2022","unstructured":"LeBlanc R, Ahmad I, Terra R, Boudreault J-S, Ogez D, Lamore K et al. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous\/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplant 2022; 57: 252\u2013260.","journal-title":"Bone Marrow Transplant"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson NK","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI: Journal of the National Cancer Institute 1993; 85: 365\u2013376.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks K","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer 2007; 43: 1670\u20131678.","journal-title":"European Journal of Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella DF","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570\u2013579.","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon RP","year":"1997","unstructured":"McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19: 357\u2013368.","journal-title":"Bone Marrow Transplant"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia MH","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation 2015; 21: 389\u2013401.e1.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","article-title":"Reliability and validity of the modified 7-day Lee Chronic-versus-Host Disease Symptom Scale","volume":"26","author":"Teh C","year":"2020","unstructured":"Teh C, Onstad L, Lee SJ. Reliability and validity of the modified 7-day Lee Chronic-versus-Host Disease Symptom Scale. Biol Blood Marrow Transplant 2020; 26: 562\u2013567.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil C","year":"2019","unstructured":"Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica 2019; 104: 370\u2013379.","journal-title":"Haematologica"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","article-title":"What changes in health-related quality of life matter to multiple myeloma patients? A prospective study*","volume":"84","author":"Kvam AK","year":"2010","unstructured":"Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study*. European Journal of Haematology 2010; 84: 345\u2013353.","journal-title":"European Journal of Haematology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/bmt.2017.190","article-title":"Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany","volume":"52","author":"Kuba K","year":"2017","unstructured":"Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L et al. Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany. Bone Marrow Transplant 2017; 52: 1651\u20131657.","journal-title":"Bone Marrow Transplant"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","article-title":"Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation","volume":"15","author":"Sherman AC","year":"2009","unstructured":"Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 12\u201320.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1002\/cncr.28323","article-title":"Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"119","author":"Jones D","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer 2013; 119: 4188\u20134195.","journal-title":"Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.clml.2022.08.002","article-title":"Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple Myeloma","volume":"22","author":"Yusuf ARS","year":"2022","unstructured":"Yusuf ARS, Heiling HM, Deal AM, Jensen CE, Mangieri NJ, Nyrop KA et al. Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2022; 22: 920\u2013927.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/pon.3159","article-title":"Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study","volume":"22","author":"Scherwath A","year":"2013","unstructured":"Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A et al. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psycho-Oncology 2013; 22: 1509\u20131516.","journal-title":"Psycho-Oncology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41409-017-0055-7","article-title":"Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT","volume":"53","author":"Buchbinder D","year":"2018","unstructured":"Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant 2018; 53: 535\u2013555.","journal-title":"Bone Marrow Transplant"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MPH.0b013e318168e750","article-title":"Progressive Declines in Neurocognitive Function Among Survivors of Hematopoietic Stem Cell Transplantation for Pediatric Hematologic Malignancies","volume":"30","author":"Shah AJ","year":"2008","unstructured":"Shah AJ, Epport K, Azen C, Killen R, Wilson K, De Clerck D et al. Progressive Declines in Neurocognitive Function Among Survivors of Hematopoietic Stem Cell Transplantation for Pediatric Hematologic Malignancies. Journal of Pediatric Hematology\/Oncology 2008; 30: 411.","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12955-020-01651-2","article-title":"\u201cIs this the GVHD?\u201d A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service","volume":"19","author":"Vere Hunt I","year":"2021","unstructured":"de Vere Hunt I, Kilgour JM, Danby R, Peniket A, Matin RN. \u201cIs this the GVHD?\u201d A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service. Health Qual Life Outcomes 2021; 19: 11.","journal-title":"Health Qual Life Outcomes"},{"year":"2013","author":"Costanzo ES","key":"ref38","unstructured":"Costanzo ES, Juckett MB, Coe CL. Biobehavioral influences on recovery following hematopoietic stem cell transplantation. Brain Behav Immun 2013; 30 Suppl: S68-74."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","article-title":"Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial","volume":"35","author":"El-Jawahri A","year":"2017","unstructured":"El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW et al. Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. J Clin Oncol 2017; 35: 3714\u20133721.","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00520-014-2452-4","article-title":"A mindfulness-based program for improving quality of life among hematopoietic stem cell transplantation survivors: feasibility and preliminary findings","volume":"23","author":"Grossman P","year":"2015","unstructured":"Grossman P, Zwahlen D, Halter JP, Passweg JR, Steiner C, Kiss A. A mindfulness-based program for improving quality of life among hematopoietic stem cell transplantation survivors: feasibility and preliminary findings. Support Care Cancer 2015; 23: 1105\u20131112.","journal-title":"Support Care Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00277-015-2509-6","article-title":"A randomized clinical trial on the effectiveness of an intervention to treat psychological distress and improve quality of life after autologous stem cell transplantation","author":"Amj B","year":"2016","unstructured":"Amj B, B van M, Oj V, Ad B, P C, Ce E et al. A randomized clinical trial on the effectiveness of an intervention to treat psychological distress and improve quality of life after autologous stem cell transplantation. Annals of hematology 2016; 95. doi:10.1007\/s00277-015-2509-6.","journal-title":"Annals of hematology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/pon.3925","article-title":"Psychological interventions for distress in adults undergoing haematopoietic stem cell transplantation: a systematic review with meta-analysis","volume":"25","author":"Baliousis M","year":"2016","unstructured":"Baliousis M, Rennoldson M, Snowden JA. Psychological interventions for distress in adults undergoing haematopoietic stem cell transplantation: a systematic review with meta-analysis. PSYCHO-ONCOLOGY 2016; 25: 400\u2013411.","journal-title":"PSYCHO-ONCOLOGY"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"9642","DOI":"10.1200\/jco.2014.32.15_suppl.9642","article-title":"Quality of life (QOL), mood, and prognostic awareness during hospitalization for hematopoietic stem cell transplantation (HSCT)","volume":"32","author":"El-Jawahri A","year":"2014","unstructured":"El-Jawahri A, Traeger L, Kuzmuk K, Eusebio J, Gallagher ER, VanDusen H et al. Quality of life (QOL), mood, and prognostic awareness during hospitalization for hematopoietic stem cell transplantation (HSCT). JCO 2014; 32: 9642\u20139642.","journal-title":"JCO"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1188\/17.ONF.96-107","article-title":"Perceptions of Hematopoietic Stem Cell Transplantation and Coping Predict Emotional Distress During the Acute Phase After Transplantation","volume":"44","author":"Baliousis M","year":"2017","unstructured":"Baliousis M, Rennoldson M, Dawson DL, Mills J, das Nair R. Perceptions of Hematopoietic Stem Cell Transplantation and Coping Predict Emotional Distress During the Acute Phase After Transplantation. Oncol Nurs Forum 2017; 44: 96\u2013107.","journal-title":"Oncol Nurs Forum"},{"year":"1980","author":"Leventhal H","key":"ref45","unstructured":"Leventhal H, Meyer D, Nerenz D. The Common Sense Representation of Illness Danger. In: Medical Psychology. 1980https:\/\/www.academia.edu\/259452\/The_Common_Sense_Representation_of_Illness_Danger (accessed 20 Dec2019)."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10865-016-9782-2","article-title":"The Common-Sense Model of Self-Regulation (CSM): a dynamic framework for understanding illness self-management","volume":"39","author":"Leventhal H","year":"2016","unstructured":"Leventhal H, Phillips LA, Burns E. The Common-Sense Model of Self-Regulation (CSM): a dynamic framework for understanding illness self-management. J Behav Med 2016; 39: 935\u2013946.","journal-title":"J Behav Med"},{"key":"ref47","first-page":"1","article-title":"The common sense model of illness self-regulation: a conceptual review and proposed extended model","author":"Hagger MS","year":"2021","unstructured":"Hagger MS, Orbell S. The common sense model of illness self-regulation: a conceptual review and proposed extended model. Health Psychology Review 2021; 0: 1\u201331.","journal-title":"Health Psychology Review"},{"key":"ref48","first-page":"138","volume-title":"The self-regulation of health and illness behaviour","author":"Horne R","year":"2003","unstructured":"Horne R. Treatment perceptions and self-regulation. In: The self-regulation of health and illness behaviour. Routledge: London, 2003, pp 138\u2013153."},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial Disparities in the Prevalence of Monoclonal Gammopathies: A population-based study of 12,482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren O","year":"2014","unstructured":"Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R et al. Racial Disparities in the Prevalence of Monoclonal Gammopathies: A population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 2014; 28: 1537\u20131542.","journal-title":"Leukemia"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4470765\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4470765\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T01:08:58Z","timestamp":1729472938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4470765\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":49,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4470765\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,6,18]]},"subtype":"preprint"}}